Skip to main navigation

Contact Us
Global
- International
- Canada
- France
- Germany
- Italy
- Japan
- Netherlands
- Spain

About Amicus
- About Amicus
- Belief Statement
- Board of Directors
- Our Founding Legacy
- Senior Management Team
- Message from the President and CEO
Patient Advocacy
- Patient Advocacy
- Rare Stories
- Patient Advisory Boards
- Resources
- Expanded Access
Programs & Pipeline
- Programs & Pipeline
- Our Pipeline
- Fabry Disease
- Pompe Disease
- Batten Disease
- Additional Preclinical Programs
- Clinical Trials
- Global Research Center
Products
- Products & Services
- Galafold^®(migalastat)
- Pombiliti^® + Opfolda^®(cipaglucosidase alfa-atga) (miglustat)
- AMICUS ASSIST^®
Responsibility
- Responsibility
- Ethics & Compliance
- Global Medical Affairs
- Corporate Giving
- Healing Beyond Disease
- ESG Report
Investors & Media
- Investors & Media
- Investor Relations
- Corporate Governance
- Press Releases
- Events & Presentations
- Annual Reports and Proxies
- SEC Filings
- Stock Performance
- Analyst Consensus
- Investor FAQs
- Contact Us
- Sign Up for Email Alerts
Careers
- Careers
- Overview
- Search

Investors

Press Releases

Press Releases

Year

January 7, 2024

Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook

January 3, 2024

Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

About Amicus

Patient Advocacy

Programs & Pipeline

Our Products

Responsibility

Investors & Media

Careers

Social Media
- Twitter
- YouTube
- LinkedIn

Copyright © 2024 Amicus Therapeutics. All rights reserved. NP-AT-ALL-00011119

Cookies Statement
Terms of Use
Privacy Notice
Privacy Shield Policy

The site you are about to enter is intended for US healthcare professionals.

Please confirm you are a US healthcare professional.

I am a US healthcare professional I am not a US healthcare professional